NCT01349348View on ClinicalTrials.gov

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

July 31, 2012

Conditions
AscitesHepatic Cirrhosis
Interventions
DRUG

Tolvaptan

tablet, 15 mg, Qd, for 7 days

DRUG

Tolvaptan

tablet, 7.5 mg, Qd, for 7 days

DRUG

placebo

tablet, 7.5/15mg , Qd, 7days.

Trial Locations (1)

200001

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY